Clinical Trial

A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)

Name: A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) — clinical trial record (NCT07576868)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-05-04.

Trial Details

NCT Number	NCT07576868
Lead Sponsor	Hyundai Bioscience Co., Ltd.
Conditions	Dengue
Enrollment	210 participants
Start Date	2026-04-09
Primary Completion	2027-01 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-10